Validation of gene therapy for heart failure
Heart failure is characterised by contractile dysfunction caused by a decreased sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity. In September 18 Circulation, Federica del Monte and colleagues from Massachusetts General Hospital show that gene transfer of SERCA2a can improve survival and the energy potential in failing hearts.del Monte et al. tested the effects of adenoviral cardiac gene transfer of SERCA2a on survival, left ventricular (LV) volumes and metabolism in a rat model of heart fa
Sep 19, 2001
Heart failure is characterised by contractile dysfunction caused by a decreased sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity. In September 18
del Monte
"This study validates the feasibility of cardiac gene transfer in failing hearts as a therapeutic modality," said the authors.